孟鲁司特钠联合布地奈德治疗小儿哮喘的临床疗效分析

Clinical Analysis of Montelukast Sodium Combined with Budesonide in the Treatment of Childhood Asthma

目的探讨小儿哮喘应用孟鲁司特钠与布地奈德联合治疗的疗效。方法选取本院儿科2014年7月~2015年7月接收治疗的110例哮喘患儿,随机分为甲组和乙组,各55例。甲组患儿单纯应用布地奈德进行治疗,乙组患儿在甲组治疗的同时联合应用孟鲁司特钠,对比两组哮喘患儿的肺功能、炎性情况以及临床疗效。结果 (1)乙组治疗后的FEV1、FVC与PEF依次为(0.89±0.20)L、(0.83±0.19)L、(90.00±18.20)L/s,均分别高于甲组的(0.78±0.30)L、(0.65±0.20)L、(81.20±21.00)L/s,差异有统计学意义(P<0.05)。(2)乙组治疗后的hs-CRP、IL-6依次为(8.00±1.29)mg/L、(44.00±12.40)pg/ml,分别低于甲组的(11.30±2.00)mg/L、(95.68±16.55)pg/ml,差异有统计学意义(P<0.05)。(3)乙组治疗总有效率为90.91%,高于甲组的72.73%,差异有统计学意义(P<0.05)。结论对哮喘患儿应用孟鲁司特钠与布地奈德联合治疗,有助于缓解呼吸道炎性症状、改善肺功能,促进临床疗效的进一步提升。

Objective To evaluate the efficacy of montelukast sodium combined with budesonide in the treatment of childhood asthma.Methods 110 children with asthma received treatment from July 2014 to July 2015 were randomly divided into two groups：group A（55 cases）and group B（55 cases）.Group A was treated with budesonide alone,group B was treated with montelukast sodium in combination with group A,and the pulmonary function,inflammatory status and clinical efficacy of two groups of asthmatic children were compared.Results（1） After treatment,FEV1,FVC and PEF in group B were（0.89 ±0.20）L,（0.83 ±0.19）L,（90.00 ±18.20）L/s,respectively,higher than those in group A（0.78 ±0.30）L,（0.65 ±0.20）L,（81.20 ±21.00）L/s,respectively,the difference was statistically significant（P〈0.05）.（2）After treatment,hs-CRPN,IL-6 in group B was（8.00±1.29）mg/L,（44.00±12.40）pg/ml,respectively,lower than that in group A（11.30 ±2.00）mg/L,（95.68 ±16.55）pg/ml,the difference was statistically significant（P〈0.05）.（3）The total effective rate of treatment in group B was 90.91%,which was higher than that in group A 72.73%,the difference was statistically significant（ P〈0.05）.Conclusion The combined therapy of montelukast sodium and budesonide is helpful to relieve respiratory inflammatory symptoms,improve lung function and promote the further improvement of clinical efficacy in asthmatic children.